New cholera vaccine trial aims to protect families in High-Risk areas
NCT ID NCT07509047
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new cholera vaccine (OSP:rTTHc CCV) in 390 healthy adults and children aged 1 to 45 in a region where cholera is common. The goal is to see if the vaccine is safe and triggers a strong immune response. Some participants get the vaccine with or without an adjuvant (alum), while others get a standard cholera vaccine or a placebo. Results will help decide the best dose and schedule for future use.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- OSP:rTTHc cholera conjugate vaccine (CCV) with or without aluminum phosphate adjuvant
- What this could lead to
- If successful, this could lead to a more effective cholera vaccine that protects adults and children with fewer doses.
- What could go wrong
- This is a phase II trial with 390 participants, so results are still early. The vaccine may not produce strong enough immunity or could have side effects not seen yet.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 390 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jan 2026
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
1 year to 45 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Individuals aged 1 to 45 years at consent 2. Participants/ Participants' legally authorized representative (LAR) willing to provide written informed consent to participate in the study voluntarily 3. Participants who can comply with the study requirements 4. Individuals in good health as determined by the outcome of medical history, physical examination, and the clinical judgment of the investigator Exclusion Criteria: 1. Known history or allergy to investigational vaccine components or other medications, or any other allergies 2. Individuals with major congenital abnormalities 3. Known history of immune function disorders including immunodeficiency diseases (known HIV infection¥ or other immune function disorders) 4. Use of systemic steroids within past 6 months (\>10 mg/day prednisone equivalent for periods exceeding 2 consecutive weeks), or receive chemotherapy, radiation therapy or other immunosuppressive drugs within the past 6 months. 5. Any abnormality or chronic disease which in the opinion of the investigator might be detrimental for the safety of the participant and interfere with the assessment of the study objectives 6. Individuals with behavioral or cognitive impairment or psychiatric disease or neural disorders that, in the opinion of the investigator, could interfere with the participant's ability to participate in the trial 7. Individuals with splenectomy 8. Individuals with known bleeding disorders 9. Receipt of blood, blood-derived products, or immunoglobulin products in the past 3 months 10. Individuals who have received other vaccines from 4 weeks prior to the first dose of test vaccination or planned to receive any vaccine within 4 weeks of the last dose of the investigational product. 11. Individuals with active or known previous Vibrio cholerae infection 12. Individuals with a history of severe diarrhea in the last 6 months requiring care at a medical facility lasting 24 hours or more 13. Individuals with prior receipt of a cholera vaccine in the last 5 years 14. Any female participant who is lactating or pregnant 15. Females of childbearing potential who do not agree to use an effective birth control method for at least 4 weeks before the screening and up to 12 weeks after the study vaccination. 16. Individuals enrolled in another clinical trial within 6 months prior to enrollment, concomitantly enrolled or scheduled to be enrolled in another trial during study period 17. Individuals who are research staff involved with the clinical trial or family/household members of research staff 18. As per Investigator's medical judgement, an individual could also be excluded from the study despite meeting all inclusion/exclusion criteria mentioned above 19. Children below 5 years old with Weight for Height Z score and/or Height for Age Z score of less than -2
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cholera vaccination are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
KAVI-Institute of Clinical Research, University
RECRUITINGNairobi, Kenyatta National Hospital Complex, 19676, Kenya
More trials for these conditions
Other studies related to the condition(s) this trial covers.